Cargando…

Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial

BACKGROUND: This study is aimed at investigating whether dapagliflozin adjunct to insulin therapy further improves glycemic control compared to insulin therapy alone in patients with newly diagnosed type 2 diabetes (T2D). METHODS: This single-centre, randomized, controlled, open-labeled trial recrui...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Lan-lan, Zhang, Peng, Liu, Bing-li, Yan, Reng-na, Ye, Lei, Ma, Jian-hua, Li, Feng-fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419509/ https://www.ncbi.nlm.nih.gov/pubmed/34497852 http://dx.doi.org/10.1155/2021/6618257

Ejemplares similares

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Li, Feng-fei, et al.
Publicado: (2016)

Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial
por: Li, Feng-fei, et al.
Publicado: (2016)

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients
por: Sun, Yue, et al.
Publicado: (2020)

Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin
por: Hu, Yun, et al.
Publicado: (2021)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015)

Glycemic variation in uncontrolled Graves’ disease patients with normal glucose metabolism: Assessment by continuous glucose monitoring
por: Gao, Gu, et al.
Publicado: (2018)

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
por: Yadegarfar, Ghasem, et al.
Publicado: (2021)

Serum ErbB2 concentration positively correlated to the glycemic variations in newly diagnosed Type 2 diabetic patients
por: Huang, Yan, et al.
Publicado: (2022)

Real-Time Flash Glucose Monitoring Had Better Effects on Daily Glycemic Control Compared With Retrospective Flash Glucose Monitoring in Patients With Type 2 Diabetes on Premix Insulin Therapy
por: Yan, Reng-na, et al.
Publicado: (2022)

Abstract 52: Clinical efficacy of dapagliflozin in patients with newly diagnosed type 2 diabetes
por: Patil, Surekha Mahesh
Publicado: (2022)

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
por: Sokolov, Victor, et al.
Publicado: (2023)

Features of glycemic variations in drug naïve type 2 diabetic patients with different HbA(1c) values
por: Li, Feng-fei, et al.
Publicado: (2017)

Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial
por: Sharma, Surendra Kumar, et al.
Publicado: (2018)

Effect of short-term intensive insulin therapy on α-cell function in patients with newly diagnosed type 2 diabetes
por: Zheng, Hai-Lan, et al.
Publicado: (2020)

Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs
por: Luo, Menghui, et al.
Publicado: (2020)

Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study
por: Kudo, Akihiro, et al.
Publicado: (2023)

Open-label placebos as adjunctive therapy for patients with depression
por: Schienle, Anne, et al.
Publicado: (2022)

Medication adherence and glycemic control among newly diagnosed diabetes patients
por: Lin, Lee-Kai, et al.
Publicado: (2017)

Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy
por: Li, Feng-fei, et al.
Publicado: (2018)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
por: Kaku, Kohei, et al.
Publicado: (2014)

Beneficial Effects of Insulin on Glycemic Control and β-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe Hyperglycemia After Short-Term Intensive Insulin Therapy
por: Chen, Harn-Shen, et al.
Publicado: (2008)

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
por: Li, Feng-fei, et al.
Publicado: (2018)

Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes
por: Li, Feng-fei, et al.
Publicado: (2017)

Use of insulin degludec/aspart after resolution of euglycemic diabetic ketoacidosis associated with dapagliflozin in a female patient with newly diagnosed maturity onset diabetes of the young type 3
por: Ayhan, Ihsan, et al.
Publicado: (2023)

Hypoglycemia during Short-Term Intensive Insulin Therapy and Its Association with Long-Term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes
por: Xu, Lijuan, et al.
Publicado: (2020)

Evaluating the role of time in range as a glycemic target during short‐term intensive insulin therapy in patients with newly diagnosed type 2 diabetes
por: Liu, Liehua, et al.
Publicado: (2023)

Liraglutide as an Alternative to Insulin for Glycemic Control in Intensive Care Unit: A Randomized, Open-label, Clinical Study
por: Verma, Vishesh, et al.
Publicado: (2017)

Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
por: Hwang, Kihwan, et al.
Publicado: (2021)

Greater Glycemic Burden Is Associated with Further Poorer Glycemic Control in Newly-Diagnosed Type 2 Diabetes Mellitus Patients
por: Wen, Wei-Lun, et al.
Publicado: (2022)

Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study
por: Zhu, Haoyue, et al.
Publicado: (2022)

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020)

The Effect of Early Insulin Therapy on Pancreatic β-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients
por: Chon, Suk, et al.
Publicado: (2010)

Self-monitoring of blood glucose in association with glycemic control in newly diagnosed non-insulin-treated diabetes patients: a retrospective cohort study
por: Sia, Hon-Ke, et al.
Publicado: (2021)

Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study
por: Araki, Eiichi, et al.
Publicado: (2021)

Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
por: Gautam, Kumar, et al.
Publicado: (2023)

Insulin Oedema in Newly Diagnosed Type 1 Diabetes Mellitus
por: Baş, Veysel Nijat, et al.
Publicado: (2010)

Periodontal therapy: A useful adjunct to improve glycemic control
por: Goyal, Lata, et al.
Publicado: (2012)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Management of Patients with Newly Diagnosed Diabetic Mellitus: Ophthalmologic Outcomes in Intensive versus Conventional Glycemic Control
por: Lam, Pun Yuet, et al.
Publicado: (2021)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Gabriel, Adel
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_48fhv4rm792lkb3prjnksft643